Immunine

Human Coagulation Factor IX, the active ingredient in Immunine, is a coagulation factor presented as a sterile solution for intravenous use. It is indicated for the treatment and prophylaxis of bleeding episodes in patients with hemophilia B (Factor IX deficiency). GNH USA supplies Immunine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity during global distribution. Customer support is available 24/7 for regulatory assistance.

Immunine is used to replace deficient factor IX in the intrinsic coagulation pathway for hemophilia B management.

- Hemophilia B (Factor IX deficiency): Restores factor IX activity to control and prevent spontaneous and traumatic bleeding. - Surgical prophylaxis in hemophilia B: Provides temporary correction of factor IX levels to reduce peri‑operative bleeding risk. - On‑demand treatment of bleeding episodes: Supplies immediate factor IX replacement to stop active hemorrhage in patients with hemophilia B.

Administration of Immunine may be associated with adverse reactions ranging from mild to severe.

Common Side Effects: - Infusion‑related reactions such as mild fever, chills, or headache. - Nausea or vomiting. - Transient hypertension or blood pressure fluctuations.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Development of neutralizing antibodies (inhibitors) to factor IX. - Thromboembolic events, including deep‑vein thrombosis.

Prior to initiating Immunine therapy, several safety considerations should be observed.

- Monitor inhibitor development: test for anti‑factor IX antibodies periodically. - Assess for allergic reactions: discontinue if severe hypersensitivity occurs. - Use caution in patients with cardiovascular disease or hypertension. - Avoid in individuals with known hypersensitivity to human plasma‑derived proteins. - Pregnancy and lactation: safety not established; weigh risks and benefits. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunine can interact with other agents that affect hemostasis or immune response.

Major Interactions (Avoid): - Concurrent anticoagulants (e.g., warfarin, heparin): may diminish therapeutic effect and increase bleeding risk. - Activated prothrombin complex concentrates: combined use can raise thrombosis risk. - Immunosuppressive therapy: may alter inhibitor formation and affect efficacy.

Moderate Interactions (Monitor Closely): - Other factor concentrates or plasma products: may increase inhibitor development. - Vaccinations (especially live vaccines): monitor for altered immune response. - CYP450‑modulating drugs: generally minimal impact but observe clinical response.